Table 3.
Characteristics of patients receiving different drug regimens in the continuation phase
| INH + Rifampicin | INH + Rifampicin + ethambutol | |
|---|---|---|
| Age in years, median, (range) | 25 (16–75) | 25 (16–76) |
| Sex, n/N (%) | ||
| Male | 46/103 (44.6) | 48/101 (47.5) |
| Female | 57/103 (55.3) | 53/101 (52.4) |
| History of contact with TB, n/N (%) | ||
| a Recent | 21/103 (20.3) | 20/101 (19.8) |
| b Previous | 17/103 (16.5) | 22/101 (21.7) |
| No history of contact | 65/103 (63.1) | 59/101 (58.4) |
| Prevalence of HIV | 0/103 | 0/103 |
| Smoker n/N (%) | 4/103 (3.8) | 10/101 (9.9) |
| Prevalence of diabetes n/N (%) | 8/103 (7.7) | 3/101 (2.9) |
| cBacillary load before treatment n/N (%) | ||
| scanty | 10/103 (9.7) | 10/101 (9.9) |
| + 1 | 57/103 (55.4) | 60/101 (59.4) |
| + 2 | 25/103 (24.2) | 12/101 (11.9) |
| + 3 | 11/103 (10.7) | 19/101 (18.8) |
| Chest X-ray n/N (%) | ||
| Cavitary lesions | 3/7 (42.9) | 4/7 (57.1) |
| Non-cavitary infiltrates | 49/95 (51.6) | 46/95 (48.4) |
| Not available | 50/102 (49.1) | 52/102 (50.9) |
n number, N Total number, % percentage
aHistory of contact with active TB case during the course of diagnosis and treatment
bHistory of contact with active TB case before diagnosis and treatment
cGraded as per guidelines of the International Union Against Tuberculosis and Lung Disease